Minor histocompatibility antigens and their use in diagnosis and treatment of tumors
CA 2359367 A1 · Owner: Dolstra, Harmen · Inventors: Van De Wiel-Van Kemenade, Petronella; Verlinden, Stefan Frederik Franciscus; Dolstra, Harmen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Human minor histocompatibility Ags (mHag) play an important role in the induction of CTL reactivity against tumours after HLA-identical allogeneic bone marrow transplantation (BMT). As most mHag are not tumour specific but also expressed by normal tissues, anti-tumour reactivity is often associated with life-threatening graft-versus-host disease (GVHD). Here we describe the , use of newly found tumour specific mHag for the development of novel means and methods for the treatment of cancer. In one example we identified a novel mHag, HB-1, that elicits donor-derived CTL reactivity in a B-cell acute lymphoblastic leukemia (B-ALL) patient treated by HLA-matched BMT. We identified the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 17, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 17, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 17, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.